Humana Inc. (LON:0J6Z)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 38.97B +69.3% |
| Revenue (ttm) | 116.14B +22.0% |
| Net Income | 938.52M -3.5% |
| EPS | 7.70 -3.7% |
| Shares Out | n/a |
| PE Ratio | 42.41 |
| Forward PE | 28.03 |
| Dividend | 2.66 (0.81%) |
| Ex-Dividend Date | Dec 24, 2026 |
| Volume | 601 |
| Open | 428.00 |
| Previous Close | 432.23 |
| Day's Range | 419.80 - 437.03 |
| 52-Week Range | 162.00 - 456.40 |
| Beta | 0.64 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About Humana
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and... [Read more]
Financial Performance
In 2025, Humana's revenue was $129.66 billion, an increase of 10.11% compared to the previous year's $117.76 billion. Earnings were $1.19 billion, a decrease of -1.57%.
Financial numbers in USD Financial StatementsNews
Humana price target raised to $484 from $393 at JPMorgan
JPMorgan analyst Lisa Gill raised the firm’s price target on Humana (HUM) to $484 from $393 and keeps a Neutral rating on the shares.
New oncology model from Humana, Evolent and American Oncology Network eliminates prior authorization burden
LOUISVILLE, Ky.--(BUSINESS WIRE)--New oncology model from Humana, Evolent and American Oncology Network eliminates prior authorization burden.
Humana price target raised to $516 from $436 at Deutsche Bank
Deutsche Bank analyst George Hill raised the firm’s price target on Humana (HUM) to $516 from $436 and keeps a Buy rating on the shares. The company reported better than…
Humana price target raised to $521 from $471 at Guggenheim
Guggenheim raised the firm’s price target on Humana (HUM) to $521 from $471 and keeps a Buy rating on the shares. Humana reported upside to Q3 EPS as favorable cost…
Humana Commences Offers to Purchase for Cash Certain of its Outstanding Debt Securities
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) (“Humana”, “we”, or “our”) today announced that it has commenced cash tender offers (collectively, the “Offers”) to purchase the outstanding n...
Humana price target raised to $526 from $463 at Piper Sandler
Piper Sandler raised the firm’s price target on Humana (HUM) to $526 from $463 and keeps an Overweight rating on the shares. The firm takes its 2027-2028 materially higher following…
Humana price target raised to $587 from $582 at Barclays
Barclays raised the firm’s price target on Humana (HUM) to $587 from $582 and keeps an Overweight rating on the shares.
Humana Earnings Call Transcript: Q3 2026
2026 adjusted EPS guidance rose to at least $9.50, with individual MA margins on track to double excluding the Stars headwind. Strong BY28 Stars results and early AEP indicators support the recovery, while higher 2027 cost trends remain a key consideration.
Humana Earnings release: Q3 2026
Humana released its Q3 2026 earnings on November 6, 2026, summarizing the period's financial results.
Humana Prepared remarks: Q3 2026
Humana filed a regulatory document on November 6, 2026 disclosing important business information.
Humana Quarterly report: Q3 2026
Humana has published its Q3 2026 quarterly earnings report on November 6, 2026.
Humana Lifts Outlook as Quarterly Revenue Jumps
Humana raised its full-year earnings outlook as consolidated income and revenue rose in the recent quarter.
Humana reports Q3 adjusted EPS (70c), consensus ($1.00)
Reports Q3 revenue $41.16B, consensus $40.89B. “Humana (HUM) is delivering positive results for our members, our patients and their health,” said Humana President and CEO Jim Rechtin. “We are also…
Humana raises FY26 adjusted EPS view to ‘at least’ $9.50 from ‘at least’ $9.00
FY26 consensus $9.16.
Humana Reports Third Quarter 2026 Financial Results; Raises Full Year 2026 Adjusted EPS Guidance
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today reported consolidated pretax results and diluted earnings per share for the quarter ended September 30, 2026 (3Q26) versus the quarter e...
Humana Aced Key Medicare Ratings. Earnings Will Spotlight Other Cost Trends.
Costs have been a stumbling block for insurers prior to this year.
Humana, athenahealth expands electronic prior authorization capabilities
Humana (HUM) and athenahealth announced an expansion of electronic prior authorization capabilities across athenahealth’s nationwide network of more than 180,000 physicians and clinicians. “The collab...
Humana and athenahealth expand electronic prior authorization capabilities nationwide, reducing administrative burden for physicians and helping patients access care faster
BOSTON & LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana and athenahealth today announced an expansion of electronic prior authorization capabilities across athenahealth's nationwide network of more than 180...
Humana Board Declares Payment of Quarterly Dividend to Stockholders
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on January 29, 2027 to st...
Did Humana Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Humana price target raised to $495 from $468 at Mizuho
Mizuho raised the firm’s price target on Humana (HUM) to $495 from $468 and keeps an Outperform rating on the shares. The firm cites the company “receiving its strong Star…
Humana announces new joint venture with BlackRock
Humana (HUM) announced it has entered into a new joint venture agreement with funds and accounts managed by HPS Investment Partners, a part of BlackRock (BLK), to manage and operate…
Humana Announces New Strategic Joint Venture with BlackRock to Manage CenterWell Senior Primary Care Clinics
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today announced it has entered into a new joint venture agreement with funds and accounts managed by HPS Investment Partners, a part of BlackR...
Humana Inc. to Release Third Quarter 2026 Results on November 6, 2026
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) will release its financial results for the third quarter 2026 (3Q26), as well as prepared management remarks (in PDF format), at 6:00 a.m. Eas...
Humana price target raised to $525 from $475 at Oppenheimer
Oppenheimer raised the firm’s price target on Humana (HUM) to $525 from $475 and keeps an Outperform rating on the shares. Following last week’s favorable Star Ratings release, the firm…